FOXO4-DRI in Thailand: Senolytic & Cellular Rejuvenation Therapy
FOXO4-DRI is a targeted senolytic peptide designed to selectively eliminate dysfunctional senescent cells by disrupting the FOXO4-p53 interaction that sustains them. In physician-supervised longevity protocols, it is used for cellular rejuvenation, tissue regeneration support, and healthy aging optimization.
Doctor-prescribed FOXO4-DRI in Thailand is available at Peptides Thailand under physician supervision, with clinical-grade, COA-verified sourcing. It is prescribed for advanced senolytic and anti-aging protocols, most appropriate for patients undergoing structured longevity medicine programs with physician oversight.
How FOXO4-DRI Works
FOXO4-DRI operates through sophisticated pathways to identify and eliminate senescent cells. Its primary mechanism involves disrupting the interaction between FOXO4 and p53 in senescent cells, leading to their selective elimination through programmed cell death. The peptide demonstrates remarkable specificity for senescent cells, helping to reduce the burden of aging cells while preserving healthy tissue function.
Medical Review Status
Last reviewed: June 2026 | Next review: December 2026
Written by Dr. Michael Ackland · Medically reviewed by Dr. Ploy Pitayanon, MD, licensed by the Medical Council of Thailand
At a Glance
Peptide
FOXO4-DRI
Category
Injectable Peptide
Dosage
As prescribed
Frequency
Per medical protocol
Administration
Subcutaneous injection
Potential Benefits
- · Targets senescent cells
- · Promotes tissue regeneration
- · Supports healthy aging
Quality Matters
Why we use Clinical-Grade only
Certificate of Analysis
Every peptide we dispense comes with a third-party COA confirming purity and potency, never grey-market sourced.
Compounded in Thailand
Manufactured in Thai FDA-licensed compounding laboratories operating under GMP standards.
Physician-prescribed only
No dispensing without a prescription. Every protocol begins with a licensed physician consultation and clinical assessment.
Medical Disclaimer
The information on this page is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or treatment. Any therapies, consultations, or prescriptions are provided only following assessment by a licensed physician and where clinically appropriate. Individual results may vary and no specific outcomes are guaranteed. Certain compounds discussed may not be approved medicines registered with the Thai FDA for specific therapeutic indications. Nothing here should be interpreted as a recommendation to self diagnose, self treat, or replace consultation with a qualified healthcare professional.
Doctor's Note
Dr. Ploy Pitayanon, MD, Medical Lead
FOXO4-DRI requires careful medical supervision and individualized dosing. Our clinics in Chiang Mai and Phuket provide comprehensive assessment, monitoring, and ongoing support to ensure safe and effective treatment outcomes.
Potential Benefits
Targets senescent cells
Promotes tissue regeneration
Supports healthy aging
Enhances organ function
Reduces age-related decline
Improves tissue health
Supports cellular renewal
Enhances recovery
Shows rejuvenating effects
Maintains tissue function
Speak with a physician
Interested in FOXO4-DRI?
All protocols require a physician assessment before any prescription is issued. Book a free video consultation with an MCT-licensed doctor.
Treatment Protocol
Dosage
As prescribed
Frequency
Per medical protocol
Duration
As determined
Administration
Subcutaneous injection
Safety guide
FOXO4-DRI Side Effects & Safety
Frequency, contraindications, and who is a good candidate
Recent FOXO4-DRI Research
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis
Demonstrated that FOXO4-DRI selectively induces apoptosis of senescent cells, restoring tissue homeostasis and improving physical fitness in aged mice (Cell, 2017).
View on PubMedFOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis via FOXO4 Nuclear Exclusion
Showed FOXO4-DRI targeted senescent keloid fibroblasts, inducing apoptosis and reducing pathological fibrosis through FOXO4 nuclear exclusion (Commun Biol, 2025).
View on PubMedTargeting Senescence-like Fibroblasts Radiosensitizes NSCLC and Reduces Radiation-induced Fibrosis
Showed that eliminating senescent-like fibroblasts combined with radiotherapy improved tumour control while reducing radiation-induced fibrotic side effects (JCI Insight, 2021).
View on PubMedRelated Peptides
Prefer to message first?
Chat with our team on WhatsApp. We typically reply within minutes.
Chat about FOXO4-DRI